Adaptive Biotechnologies (ADPT) EBITDA (2018 - 2026)

Adaptive Biotechnologies has disclosed EBITDA across 9 years of filings, most recently posting -$10.4 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$10.4 million, down 12.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.5 million (up 135.63% YoY), and the FY2025 annual result was $15.2 million, up 162.22% from the prior year.
• EBITDA came in at -$10.4 million for Q1 2026 at Adaptive Biotechnologies, down from -$1.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $23.7 million in Q3 2025 to a low of -$63.1 million in Q1 2022.
• The 5-year median for EBITDA is -$11.3 million (2024), against an average of -$20.0 million.
• Peak annual rise in EBITDA reached 554.83% in 2025, while the deepest fall reached 117.23% in 2025.
• Adaptive Biotechnologies' EBITDA stood at -$39.2 million in 2022, then jumped by 74.59% to -$10.0 million in 2023, then soared by 202.98% to $10.3 million in 2024, then tumbled by 117.23% to -$1.8 million in 2025, then plunged by 486.3% to -$10.4 million in 2026.
• The last three EBITDA figures came in at -$10.4 million (Q1 2026), -$1.8 million (Q4 2025), and $23.7 million (Q3 2025), per Business Quant data.